HC Wainwright Estimates GALT's Q1 Earnings

Analysts project a loss of $0.06 per share for the biotech firm's first quarter.

Apr. 2, 2026 at 11:36am

Got story updates? Submit your updates here. ›

Equities researchers at HC Wainwright have issued their Q1 2026 earnings per share estimates for shares of Galectin Therapeutics Inc. (NASDAQ:GALT). The firm's analyst M. Keller expects the company to post a loss of $0.06 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock.

Why it matters

Galectin Therapeutics is a clinical-stage biotech company focused on developing novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. Investors will be closely watching the company's Q1 earnings report for signs of progress in its drug development pipeline.

The details

In addition to the Q1 estimate, HC Wainwright also issued projections for Galectin Therapeutics' full-year 2026 earnings, with a consensus estimate of a $0.73 loss per share. The firm also provided estimates for Q2 2026 (-$0.07 EPS), Q3 2026 (-$0.09 EPS) and Q4 2026 (-$0.10 EPS).

  • HC Wainwright issued its Q1 2026 EPS estimates on Tuesday, March 31st.

The players

Galectin Therapeutics Inc.

A clinical-stage biotechnology company focused on developing novel therapies that target galectin proteins.

M. Keller

An analyst at HC Wainwright who covers Galectin Therapeutics.

HC Wainwright

An equities research firm that covers Galectin Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.06) for the quarter.”

— M. Keller, Analyst

What’s next

Investors will be watching for Galectin Therapeutics to report its actual Q1 2026 earnings, which are expected to be released in late April or early May.

The takeaway

Galectin Therapeutics' Q1 earnings projection from HC Wainwright provides insight into the biotech firm's near-term financial performance as it continues to advance its drug development pipeline for fibrotic and inflammatory diseases.